Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Propylene glycol

Classification: B

Drug products: Locobase LPL, Oviderm, Propyderm®, Propylenglykol APL, Propylenglykol Evolan, Propylenglykol i Decubal® kräm APL, Propylenglykol i Essex B kräm APL, Propylenglykol i Essex kräm APL, Propylenglykol i Locobase® kräm APL, Propylenglykol i Locobase® lotion APL, Propyless®, Propysal

ATC code: D01AE, D02AX

Substances: propylene glycol

Summary

Published controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of topical propylene glycol are lacking.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical propylene glycol have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of topical propylene glycol have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding the adverse effects of topical propylene glycol have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men [1].

Updated: 2022-09-22

Date of litterature search: 2022-06-29

References

  1. Nyberg F, Osika I, Evengård B. "The Laundry Bag Project"--unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol. 2008;47:144-9. PubMed
  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.] länk
  3. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2021 [cited 2022-06-29.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg

Approved by: Karin Schenck-Gustafsson